|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are phase 3 clinical trials underway evaluating anti-PD-L1 antibodies as adjuvant (postoperative) monotherapies for resectable renal cell carcinoma (RCC) and triple-negative breast cancer (TNBC); in combination with antiangiogenic VEGF/VEGFR2 inhibitors (e.g., bevacizumab and sunitinib) for metastatic RCC; and in combination with chemotherapeutics as neoadjuvant (preoperative) therapies for resectable TNBC.
|
30498230 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It drives tumorigenesis by activating downstream hypoxia responsive genes and proangiogenic factors like VEGFR, and is responsible for the activity of tyrosine kinase inhibitors in RCC.
|
31184937 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these data suggest that combination of S1P1 and VEGFR-targeted therapy may be a useful therapeutic strategy for the treatment of renal cell carcinoma and other tumor types.
|
30787172 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among patients treated with adjuvant VEGFR TKIs for RCC, drug-host interactions mediate changes in circulating cytokines.
|
31471309 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we used a coculture model of human umbilical vein endothelial cells with RCC cell lines to find out that HMGB1 also increased the expression of VEGF and VEGFR2 in human umbilical vein endothelial cells.
|
30122942 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over the past decade, therapies targeting the VEGF/VEGFR and mTOR pathways have served as the standard of care for the clinical management of renal cell carcinoma (RCC) patients.
|
29930727 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Axitinib is an approved drug that targets the vascular endothelial growth factor receptor 2 (VEGFR2) and is licensed for second-line therapy of renal cell carcinoma.
|
30199151 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tivozanib received its first global approval in EU, Iceland, and Norway on 28 August 2017 for the first-line treatment of adult patients with advanced RCC and for adult patients who are VEGFR and mTOR inhibitor-naive following disease progression after one prior treatment with cytokines.
|
29851529 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of a VEGFR-TKI and immunotherapy is promising in advanced RCC, if the treatment regimens have acceptable tolerability.
|
30084668 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we review the results of recently completed adjuvant vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) trials in RCC that have been reported, or are awaiting results.
|
29051029 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
658 patients with advanced RCC who had received at least one prior VEGFR tyrosine kinase inhibitor were randomised 1:1 to cabozantinib (60 mg daily) or everolimus (10 mg daily).
|
29576624 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renal cell carcinoma (RCC) is highly dependent on angiogenesis, due to the overactivation of the VHL/HIF/VEGF/VEGFRs axis; this justifies the marked sensitivity of this neoplasm to antiangiogenic agents which, however, ultimately fail to control tumor growth.
|
30447930 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To systematically evaluate the current evidence regarding the therapeutic benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3-4 adverse events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC.
|
29784193 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nivolumab has emerged as a promising new therapy in advanced malignancies, and the first agent to show survival advantage in patients failing prior VEGFR-targeted therapy in metastatic RCC.
|
29460635 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the phase III METEOR trial, tyrosine kinase inhibitor cabozantinib significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival compared to everolimus in patients with advanced renal cell carcinoma (RCC) who had received prior VEGFR inhibitor therapy.
|
29667066 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structure-Based Virtual Screening for the Identification of High Affinity Compounds as Potent VEGFR2 Inhibitors for the Treatment of Renal Cell Carcinoma.
|
30499413 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has recently been approved by the European Medicines Agency (EMA) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive, following disease progression after one prior treatment with cytokine therapy for advanced RCC.
|
29451277 |
2017 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
|
27248821 |
2016 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There are no effective therapies for advanced renal cell carcinoma (RCC), except for VEGFR inhibitors with only ~50% response rate.
|
27035563 |
2016 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that S1P inhibition may be a novel therapeutic strategy in patients with treatment-naïve RCC and also in the setting of resistance to VEGFR TKI therapy.
|
25589614 |
2015 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings demonstrate for the first time that CHIP may be involved in RCC angiogenesis through regulating VEGF secretion and expression of VEGFR2.
|
26021863 |
2015 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to analyze the potential relationship between miRNA-185, VEGFR-2, and angiogenesis in samples from renal cell carcinoma (RCC) patients.
|
25217984 |
2014 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data have important implications for combination therapy design, supporting the conclusion that targeting VEGFR2 alone in RCC has the potential to have pleiotropic effects on tumor stroma.
|
21245940 |
2011 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, VEGFR-2 antibody (DC101) inhibited growth of RenCa renal cell carcinoma lung metastases by 26%, whereas VEGFR-1 antibody (MF-1) had no effect.
|
20978198 |
2010 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Beyond well-validated signaling targets such as VHL, VEGFR and mTOR, additional pathways including HGF/c-MET and Wnt/β-catenin have emerged as important to RCC pathogenesis.
|
20814228 |
2010 |